AE Wealth Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-1,261
Closed -$218K 2695
2026
Q1
$218K Sell
1,261
-219
-15% -$40.6K ﹤0.01% 1565
2025
Q4
$295K Buy
+1,480
New +$268K ﹤0.01% 1318
2022
Q1
Sell
-611
Closed -$230K 1696
2021
Q4
$230K Sell
611
-10
-2% -$3.88K ﹤0.01% 1551
2021
Q3
$256K Sell
621
-3
-0.5% -$1.25K ﹤0.01% 1425
2021
Q2
$231K Buy
+624
New +$208K ﹤0.01% 1445

Other funds holding CRL

AE Wealth Management's CRL Position: Q2 2026 in Review

AE Wealth Management sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 1,261 shares — an estimated $218K sold.

AE Wealth Management first reported a position in CRL in Q2 2021 and held it in 5 quarters. The position peaked at $295K in Q4 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • AE Wealth Management reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • AE Wealth Management sold 1,261 Charles River Laboratories shares in Q2 2026, an estimated $218K.
  • AE Wealth Management first reported a position in Charles River Laboratories in Q2 2021 and held it in 5 quarters.
  • AE Wealth Management's Charles River Laboratories position peaked at $295K in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on AE Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.